Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

[6] In this regard, monitoring of JC and BK viremia might not only allow for early recognition and therapy of polyomavirus nephropathy, but may also provide an indirect assessment of the state of ...